Definium posts late-stage trial win for LSD drug (DFTX:NASDAQ)
· seekingalpha.com
Definium Therapeutics (DFTX) stock rises as the company succeeds in a late-stage trial for its LSD-based psychiatric treatment against anxiety. Read more here.
Definium Therapeutics (DFTX) on Wednesday announced that a late-stage trial for DT120, its LSD-based psychiatric treatment, reached the main goal in patients wi...